FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Imeka Brain White Matter Imaging Cleared

FDA clears an Imeka 510(k) for its Advanced Neuro Diagnostic Imaging (ANDI) quantitative imaging software, which is intended to generate a report for ...

latest-news-card-1
Federal Register

Meeting on Study Disruptions During Emergencies

Federal Register notice: FDA announces a 10/18-19 public meeting entitled Mitigating Clinical Study Disruptions During Disasters and Public Health Eme...

latest-news-card-1
Federal Register

Guide on User Fee Waivers for HIV Drugs

Federal Register notice: FDA posts a draft guidance entitled PDUFA Waivers, Reductions, and Refunds for Fixed-Combinations and Single-Entity Versions ...

latest-news-card-1
Federal Register

Guide on Antiretrovirals for HIV1 Under PEPFAR

Federal Register notice: FDA makes available a draft guidance entitled Fixed-Combinations and Single-Entity Versions of Previously Approved Antiretrov...

latest-news-card-1
Human Drugs

DSCSA Can Lead to Drug Shortages: Reps

A bipartisan group of 28 House members asks FDA about the potential for drug shortages if supply chain members cant meet the 11/27 deadline for Drug S...

latest-news-card-1
Human Drugs

DSCSA Waiver, Exception, Exemption Guidance

FDA publishes a guidance explaining the process for requesting a waiver, exception, or exemption from provisions of the Drug Supply Chain Security Act...

latest-news-card-1
Human Drugs

WLF Claims Win In Lexapro Case Dismissal

Washington Legal Foundation says the 2nd Circuit Court of Appeals upheld the dismissal of a case against Forest Pharmaceuticals over its Lexapro, agre...

latest-news-card-1
Human Drugs

CDER into Bispecific Antibody Research, Application

An FDA online paper describes CDER research into and clinical applications of bispecific antibodies.

latest-news-card-1
Human Drugs

Regeneron Responding to Eylea Complete Response

Regeneron says it will respond to a recent FDA complete response letter on the companys BLA for a higher dose of Eylea (aflibercept) 8 mg to treat pat...

latest-news-card-1
Biologics

RenatiLabs Illegally Marketing WJMAX

FDA warns Erlanger, KY-based RenatiLabs that it is illegally marketing human cell products that are manufactured with significant CGMP deviations.